Navigation Links
Chicago-Area Pediatricians Offering Unique Test to Detect Vision Problems in Children as Young as Six Months of Age
Date:5/26/2009

Area Pediatric Offices Now Offering the Enfant(TM) Pediatric VEP Vision Testing System, Providing Early Detection for Better Treatment Outcomes

CHICAGO, May 26 /PRNewswire/ -- If your child had vision problems, you'd be able to tell, wouldn't you? Maybe not, says Barry Goldman, M.D., pediatrician at Children's Health Center in Gurnee.

"Children are incredibly adaptable and learn to cope with vision deficits, even those they've had since birth," says Dr. Goldman "This allows many childhood vision problems to go undetected, which can lead to learning issues and behavioral problems, especially as children enter school and have difficulties as a result."

Approximately 200,000 children are born each year with vision deficits, making vision problems one of the most common pediatric health issues in the United States. However, until a child can accurately respond verbally to the letters on a standard eye chart (typically around school age), it is often difficult, even for doctors, to determine if a child is seeing properly. However, a new, child-friendly test being offered by Dr. Goldman's practice and several others in the Chicago area is providing parents with objective information about the development and function of their children's vision system.

Using Visual Evoked Potential (VEP) technology, the Enfant(TM) Pediatric VEP Testing System provides pediatricians with a unique diagnostic tool to assess patients as young as six months of age. Treatment of a vision deficit is most successful when it is detected early.

The Enfant objectively detects issues earlier than traditional vision tests because it works by using VEP and proprietary software to evaluate the child's entire vision system (from the eye to the brain) without the need for the patient to respond. The test utilizes a flat panel screen that features fun, child-friendly characters and gra
'/>"/>

SOURCE Diopsys
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
2. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
3. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
4. Beckman Coulter Prices $500 Million Senior Notes Offering
5. Dendreon Announces Closing of Common Stock Offering
6. Dendreon Announces Common Stock Offering
7. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
8. PharmAthene Announces $5.5 Million Public Equity Offering
9. Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock
10. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
11. Simbionix Increases Product Offerings for OB/GYN Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... WASHINGTON, June 15 Congressional Quarterly presents a 360-degree ... of follow-on versions of biotech drugs. This CQ Forum ... interest groups, and leading researchers regarding the complex structures ... possible? Will the availability of these products save money ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... of shares of convertible preferred stock pursuant to a registered ... of approximately $2 million. The preferred stock is convertible into ... investor at a price of $0.1105 per share. , ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), ... oncology, today reported that patient follow-up in the open-label ... in benign prostatic hyperplasia (BPH) with its lead endocrinology ... the end of this week. Therefore, data analysis and ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Researchers from the University of Illinois at Chicago have ... role in breaking down and inhibiting the formation of ... was published online this week in Nature Cell ... specialized cells are "recruited" to the wound site that ...
... and watched electrons flow through them, proving that single-molecule ... nanoscale science experiments. The finding, reported in the ... probes the effects of strong electron interactions that can ... size limit--single-molecule devices. The work resulted in the first ...
... National Eye Institute (NEI), part of the National Institutes ... translate molecular and genetic approaches from the laboratory to ... director Francis S. Collins, M.D., Ph.D., will deliver a ... feature discussions about cutting-edge treatment strategies as well as ...
Cached Biology News:Researchers discover mechanism that limits scar formation 2Stretching molecules yields new understanding of electricity 2National Eye Institute hosts Translational Research and Vision Symposium 2
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Request Info...
... is a fast and efficient ... Its high capacity and reliable design ... walk away time than typical stackers. ... set-up make for a seamless and ...
... MLF1 Interacting Protein/PBIP1 (phospho T78) ( ... Antigen: Synthetic ... 73-83 of Human MLF1 Interacting Protein ... 359815 Swiss ...
Biology Products: